PC protect.jpg

AndreyPopov/Getty Images

Direct Lending

Unither Pharmaceuticals private credit providers eye loan repricing in effort to stave-off bank lenders

Unither Pharmaceuticals is looking to reprice its incumbent unitranche loan in an effort to fend off potential refinancing from the broadly syndicated market, according to sources.

Unither Pharmaceuticals is looking to reprice its incumbent unitranche loan in an effort to fend off potential refinancing from the broadly syndicated market, according to market sources.

The company is seeking to lower pricing by 50 to 75 bps, sources said.

The loan dates from the acquisition of the company in 2022 by an investor consortium that included GIC, IK Partners, Keensight and Parquest.

The unitranche was provided by Arcmont and Barings. At the time, the company was marketed at roughly €90 million EBITDA during the sale, with debt leverage around 4.5x. The debt totals roughly €440 million, sources said.

“It is more than likely that direct lenders were prepared for either repricings or refinancings when the public market was shut, because they knew they could be pushed once the market reopened, so repricings are not really a surprise in this context,” one lender said.

In 2018, the company placed a €305 million covenant-lite term loan B for refinancing via sole lead Natixis. The TLB priced at E+375, with a 0% floor and par offer price.

Unither develops and manufactures sterile unit-doses for the pharmaceutical industry, addressing the ophthalmology, respiratory and rhinology markets. The company runs seven manufacturing sites in addition to its research and development center, and is present in France, the US, China and Brazil.

AndreyPopov/Getty Images

Learn about our editorial standards.